China Encourages Production of 34 Generic Medicines
International students/employees oftentimes see a specific section of Generics drug and Brand-name drug within their international student insurance (aka 留学生 保险), J-1 visa insurance (aka j1 签证 保险), and/or H-1B insurance (aka h1b 保险). Even if they waive university insurance in the United States (aka waive 美国大学保险), the alternative insurance plan also differentiate two types of drugs. Many of them are always confused about the difference between Generics and Brand-name drugs.
The U.S. Food and Drug Administration (FDA) requires generic drugs to have the same performance and quality as brand name drugs. The FDA says, “When a generic drug product is approved, it has met rigorous standards established by the FDA with respect to identity, strength, quality, purity, and potency.” Cost is the main difference between generic and brand name prescription drugs. Unlike brand companies, generic manufacturers compete directly on price, resulting in lower prices for consumers. Generics have saved Americans $1.67 trillion over the last decade. This is why the copayment of Generics is usually less than that of Brand-name drugs, and the copayment of Generics and Brand-name drugs in H-1B medical insurance (aka h1b 医保) is different than in J-1 insurance in the United States (aka 美国j1保险).
Chinese authorities on Friday released a list of 34 generic medicines, encouraging pharmaceutical firms to develop and produce them. Anti-AIDS drugs Rilpivirine and Abacavir, and leukemia drug Azathioprine are included in the list issued by the National Health Commission (NHC). The 34 medicines were proposed by experts from the NHC, the Ministry of Science and Technology, the Ministry of Industry and Information Technology, the National Medical Products Administration and the National Intellectual Property Administration.
The patents of these drugs are either expired or will soon expire with no fresh applications for registration, according to a statement concerning the list, which also includes drugs that are in short supply. The list is the first of its kind in the country and new lists will be published at the end of each year starting 2020.